Download PDF
Horm Metab Res 2022; 54(01): 7-11
DOI: 10.1055/a-1668-0094
Endocrine Care

Risk Patterns of Distant Metastases in Follicular, Papillary and Medullary Thyroid Cancer

Andreas Machens 
1   Department of Visceral, Vascular and Endocrine Surgery, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
,
Kerstin Lorenz
1   Department of Visceral, Vascular and Endocrine Surgery, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
,
Frank Weber
2   Department of General, Visceral and Transplantation Surgery, University of Duisburg-Essen, Essen, Germany
,
Henning Dralle
1   Department of Visceral, Vascular and Endocrine Surgery, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
2   Department of General, Visceral and Transplantation Surgery, University of Duisburg-Essen, Essen, Germany
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

This study of 542 patients with follicular thyroid cancer, 366 patients with the follicular variant and 1452 patients with the classical variant of papillary thyroid cancer, and 819 patients with sporadic medullary thyroid cancer operated at a tertiary referral center aimed to determine risk patterns of distant metastasis for each tumor entity, which are ill-defined. On multivariable logistic regression analyses, lymph node metastasis consistently emerged as an independent risk factor of distant metastasis, yielding odds ratios (ORs) of 2.4 and 2.8 for follicular thyroid cancer and the follicular variant of papillary thyroid cancer, and ORs of 5.9 and 6.4 for the classical variant of papillary thyroid cancer and sporadic medullary thyroid cancer. Another independent risk factor consistently associated with distant metastasis, most strongly in follicular thyroid cancer and the follicular variant of papillary thyroid cancer (OR 3.5 and 4.0), was patient age >60 years. Altogether, 2 distinct risk patterns of distant metastasis were identified, which were modulated by other cancer type-dependent risk factors: one with lymph node metastasis as leading component (classical variant of papillary thyroid cancer and sporadic medullary thyroid cancer), and another one with age as leading component (follicular thyroid cancer and the follicular variant of papillary thyroid cancer). Distant metastasis was exceptional in node-negative patients with sporadic medullary thyroid cancer (1.7%) and the classical variant of papillary thyroid cancer (1.4%), and infrequent in node-negative patients with the follicular variant of papillary thyroid cancer (4.4%). These findings delineate windows of opportunity for early surgical intervention before distant metastasis has occurred.

Key words

thyroid carcinoma - primary tumor size - lymph node metastasis - distant metastasis - patient age - risk factor


Publication History

Received: 08 September 2021

Accepted after revision: 09 October 2021

Article published online:
10 November 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Fagin JA, Wells SA. Biologic and clinical perspectives on thyroid cancer. N Engl J Med 2016; 375: 1054-1067
    CrossrefPubMedGoogle Scholar
  • 2 Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet 2016; 388: 2783-2795
    CrossrefPubMedGoogle Scholar
  • 3 Machens A, Lorenz K, Weber F. et al. Exceptionality of distant metastases in node-negative hereditary and sporadic medullary thyroid cancer: lessons learned. J Clin Endocrinol Metab 2021; 106: e2968-e2979
    CrossrefPubMedGoogle Scholar
  • 4 Dralle H, Musholt TJ, Schabram J. et al. German societies of general and visceral surgery; endocrinology; nuclear medicine; pathology; radiooncology; oncological hematology; and the German thyroid cancer patient support organization Ohne Schilddrüse leben e.V. German association of endocrine surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg 2013; 398: 347-375
    CrossrefPubMedGoogle Scholar
  • 5 DeLellis, RA, Lloyd, RV, Heitz, PU et al. Pathology and genetics of tumours of endocrine organs; In: WHO classification of tumours of endocrine organs. World Health Organisation Classification, 3rd edition, 2017
    PubMed
  • 6 Rajan N, Khanal T, Ringel MD. Progression and dormancy in metastatic thyroid cancer: Concepts and clinical implications. Endocrine 2020; 70: 24-35
    CrossrefPubMedGoogle Scholar
  • 7 Gerull WD, Puri V, Kozower BD. The epidemiology and biology of pulmonary metastases. J Thorac Dis 2021; 13: 2585-2589
    CrossrefPubMedGoogle Scholar
  • 8 Vogelstein B, Kinzler KW. The path to cancer – three strikes and you're out. N Engl J Med 2015; 373: 1895-1898
    CrossrefPubMedGoogle Scholar
  • 9 Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014; 159: 676-690
    CrossrefPubMedGoogle Scholar
  • 10 Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 2015; 347: 78-81
    CrossrefPubMedGoogle Scholar
  • 11 Elisei R, Molinaro E, Agate L. et al. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab 2010; 95: 1516-1527
    CrossrefPubMedGoogle Scholar
  • 12 Völzke H, Lüdemann J, Robinson DM. et al. The prevalence of undiagnosed thyroid disorders in a previously iodine-deficient area. Thyroid 2013; 13: 803-810
    CrossrefPubMedGoogle Scholar